Replies to post #1761 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA FY2Q19 CC transcript:

https://finance.yahoo.com/news/edited-transcript-enta-earnings-conference-040211500.html

[DewDiligence]

ENTA FY3Q19 results:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Third-Quarter-Ended-June-30-2019/default.aspx

FY3Q19 royalty revenue=$44.4M, up from $39.6M in FY2Q19 (Jan-Mar 2019).

ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year; the royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.

ENTA’s 6/30/19 cash balance=$389.2M.

FY3Q19 GAAP EPS=$0.33 (including an $0.04 tax credit).